Base de dados : MEDLINE
Pesquisa : D25.479.517 [Categoria DeCS]
Referências encontradas : 39553 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3956 ir para página                         

  1 / 39553 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29238190
[Au] Autor:Salade L; Wauthoz N; Deleu M; Vermeersch M; De Vriese C; Amighi K; Goole J
[Ad] Endereço:Laboratoire de Pharmacie Galénique et de Biopharmacie, Université libre de Bruxelles (ULB), Brussels.
[Ti] Título:Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia.
[So] Source:Int J Nanomedicine;12:8531-8543, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:The aim of the present study was to develop a ghrelin-containing formulation based on liposomes coated with chitosan intended for nose-brain delivery for the treatment of cachexia. Among the three types of liposomes developed, anionic liposomes provided the best results in terms of encapsulation efficiency (56%) and enzymatic protection against trypsin (20.6% vs 0% for ghrelin alone) and carboxylesterase (81.6% vs 17.2% for ghrelin alone). Ghrelin presented both electrostatic and hydrophobic interactions with the anionic lipid bilayer, as demonstrated by isothermal titration calorimetry. Then, anionic liposomes were coated with -(2-hydroxy) propyl-3-trimethyl ammonium chitosan chloride. The coating involved a size increment from 146.9±2.7 to 194±6.1 nm, for uncoated and coated liposomes, respectively. The ζ-potential was similarly increased from -0.3±1.2 mV to 6±0.4 mV before and after coating, respectively. Chitosan provided mucoadhesion, with an increase in mucin adsorption of 22.9%. Enhancement of permeation through the Calu3 epithelial monolayer was also observed with 10.8% of ghrelin recovered in the basal compartment in comparison to 0% for ghrelin alone. Finally, aerosols generated from two nasal devices (VP3 and SP270) intended for aqueous dispersion were characterized with either coated or uncoated liposomes. Contrarily to the SP270 device, VP3 device showed minor changes between coated and uncoated liposome aerosols, as shown by their median volume diameters of 38.4±5.76 and 37.6±5.74 µm, respectively. Overall, the results obtained in this study show that the developed formulation delivered by the VP3 device can be considered as a potential candidate for nose-brain delivery of ghrelin.
[Mh] Termos MeSH primário: Caquexia/tratamento farmacológico
Sistemas de Liberação de Medicamentos/métodos
Grelina/administração & dosagem
Lipossomos/administração & dosagem
Lipossomos/química
[Mh] Termos MeSH secundário: Administração Intranasal/instrumentação
Adsorção
Aerossóis/química
Encéfalo/efeitos dos fármacos
Quitosana/análogos & derivados
Quitosana/química
Estabilidade de Medicamentos
Grelina/química
Seres Humanos
Interações Hidrofóbicas e Hidrofílicas
Mucinas/metabolismo
Compostos de Amônio Quaternário/química
Eletricidade Estática
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Ghrelin); 0 (Liposomes); 0 (Mucins); 0 (N-(2-hydroxypropyl)-3-trimethylammonium chitosan); 0 (Quaternary Ammonium Compounds); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S147650


  2 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29238188
[Au] Autor:Zhang J; Tang H; Liu Z; Chen B
[Ad] Endereço:Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing.
[Ti] Título:Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy.
[So] Source:Int J Nanomedicine;12:8483-8493, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Chemotherapy is still one of the main cancer therapy treatments, but the curative effect of chemotherapy is relatively low, as such the development of a new cancer treatment is highly desirable. The gradual maturation of nanotechnology provides an innovative perspective not only for cancer therapy but also for many other applications. There are a diverse variety of nanoparticles available, and choosing the appropriate carriers according to the demand is the key issue. The performance of nanoparticles is affected by many parameters, mainly size, shape, surface charge, and toxicity. Using nanoparticles as the carriers to realize passive targeting and active targeting can improve the efficacy of chemotherapy drugs significantly, reduce the mortality rate of cancer patients, and improve the quality of life of patients. In recent years, there has been extensive research on nanocarriers. In this review, the effects of several major parameters of nanoparticles on their physical and chemical properties are reviewed, and then the recent progress in the application of several commonly used nanoparticles is presented.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Portadores de Fármacos/química
Sistemas de Liberação de Medicamentos/métodos
Nanopartículas/efeitos adversos
Nanopartículas/química
[Mh] Termos MeSH secundário: Dendrímeros/administração & dosagem
Dendrímeros/química
Portadores de Fármacos/farmacologia
Seres Humanos
Lipossomos/administração & dosagem
Lipossomos/química
Micelas
Nanopartículas/administração & dosagem
Nanotecnologia/métodos
Nanotubos de Carbono/química
Neoplasias/tratamento farmacológico
Tamanho da Partícula
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Dendrimers); 0 (Drug Carriers); 0 (Liposomes); 0 (Micelles); 0 (Nanotubes, Carbon)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S148359


  3 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200850
[Au] Autor:Aliu H; Rask C; Brimnes J; Andresen TL
[Ad] Endereço:Immunology Department, In vivo Biology Team, ALK Abelló A/S, Hørsholm.
[Ti] Título:Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen.
[So] Source:Int J Nanomedicine;12:8377-8388, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling more efficient delivery and hence lower allergen load might reduce the adverse events. In the present study, we have investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome carriers' ability to improve tolerance induction of antigens compared to the corresponding dose of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsulated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually treated with OVA-liposomes showed a significant reduction of airway eosinophilia and splenocyte proliferation in comparison to free OVA. A similar nonsignificant pattern was seen for OVA-specific IgE antibodies. In addition, reduced levels of interferon-γ and interleukin-5 were observed in spleen cell culture supernatants from OVA-liposome-treated mice compared to the sham-treated group. In conclusion, in vivo efficacy data showed that prophylactic SLIT with OVA-liposomes is significantly more effective in preventing allergic inflammation than the corresponding dose of free OVA.
[Mh] Termos MeSH primário: Alérgenos/administração & dosagem
Sistemas de Liberação de Medicamentos
Imunoterapia Sublingual
[Mh] Termos MeSH secundário: Alérgenos/imunologia
Animais
Citocinas/metabolismo
Ensaio de Imunoadsorção Enzimática
Feminino
Lipídeos/química
Lipossomos
Camundongos Endogâmicos BALB C
Ovalbumina/imunologia
Pneumonia/imunologia
Pneumonia/patologia
Pneumonia/prevenção & controle
Baço/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); 0 (Cytokines); 0 (Lipids); 0 (Liposomes); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S137033


  4 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461099
[Au] Autor:Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
[Ad] Endereço:Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
[Ti] Título:Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
[So] Source:J Control Release;255:210-217, 2017 Jun 10.
[Is] ISSN:1873-4995
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Many therapeutic strategies have been applied in efforts to conquer the development and/or progression of cancer. The combination of chemotherapy and an RNAi-based approach has proven to be an efficient anticancer therapy. However, the feasibility of such a therapeutic strategy has been substantially restricted either by the failure to achieve the efficient delivery of RNAi molecules to tumor tissue or by the immunostimulatory response triggered by RNAi molecules. In this study, therefore, we intended to investigate the efficacy of using liposomal oxaliplatin (liposomal l-OHP) to guarantee the efficient delivery of RNAi molecules, namely shRNA against thymidylate synthase (TS shRNA) complexed with cationic liposome (TS shRNA-lipoplex), to solid tumors, and to suppress the immunostimulatory effect of RNAi molecules, TS shRNA, following intravenous administration. Herein, we describe how liposomal l-OHP enhanced the intra-tumor accumulation of TS shRNA-lipoplex and significantly reduced the immunostimulatory response triggered by TS shRNA. Consequently, such enhanced accumulation of TS shRNA-lipoplex along with the cytotoxic effect of liposomal l-OHP led to a remarkable tumor growth suppression (compared to mono-therapy) following systemic administration. Our results, therefore, may have important implications for the provision of a safer and more applicable combination therapy of RNAi molecules and anti-cancer agents that can produce a more reliable anti-tumor effect.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Neoplasias/terapia
Compostos Organoplatínicos/administração & dosagem
RNA Interferente Pequeno/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/química
Antineoplásicos/farmacocinética
Antineoplásicos/uso terapêutico
Linhagem Celular Tumoral
Citocinas/metabolismo
Seres Humanos
Lipossomos
Masculino
Camundongos Endogâmicos BALB C
Camundongos Nus
Neoplasias/genética
Neoplasias/metabolismo
Compostos Organoplatínicos/química
Compostos Organoplatínicos/farmacocinética
Compostos Organoplatínicos/uso terapêutico
Polietilenoglicóis/química
Interferência de RNA
RNA Interferente Pequeno/química
RNA Interferente Pequeno/farmacocinética
RNA Interferente Pequeno/uso terapêutico
Timidilato Sintase/genética
Distribuição Tecidual
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cytokines); 0 (Liposomes); 0 (Organoplatinum Compounds); 0 (RNA, Small Interfering); 04ZR38536J (oxaliplatin); 30IQX730WE (Polyethylene Glycols); EC 2.1.1.45 (Thymidylate Synthase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29180864
[Au] Autor:Shi J; Su Y; Liu W; Chang J; Zhang Z
[Ad] Endereço:School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou.
[Ti] Título:A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance.
[So] Source:Int J Nanomedicine;12:8257-8275, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Recently, stimuli-responsive drug delivery systems (DDSs) with high spatial/temporal resolution bring many benefits to cancer treatment. However, cancer cells always develop ways to resist and evade treatment, ultimately limit the treatment efficacy of the DDSs. Here, we introduce photo-activated nanoliposomes (PNLs) that impart light-induced cytotoxicity and reversal of drug resistance in synchrony with a photoinitiated and rapid release of antitumor drug. The PNLs consist of a nanoliposome doped with a photosensitizer (hematoporphyrin monomethyl ether [HMME]) in the lipid bilayer and an antitumor drug doxorubicin (DOX) encapsulated inside. PNLs have several distinctive capabilities: 1) carrying high loadings of DOX and HMME and releasing the payloads in a photo-cleavage manner with high spatial/temporal resolution at the site of actions via photocatalysis; 2) reducing drug efflux in MCF-7/multidrug resistance cells via decreasing the level of P-glycoprotein induced by photodynamic therapy (PDT); 3) accumulating in tumor site taking advantage of the enhanced permeability and retention effect; and 4) combining effective chemotherapy and PDT to exert much enhanced anticancer effect and achieving significant tumor regression in a drug-resistant tumor model with little side effects.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Sistemas de Liberação de Medicamentos/métodos
Resistência a Medicamentos Antineoplásicos/efeitos dos fármacos
Lipossomos/administração & dosagem
Fotoquimioterapia/métodos
[Mh] Termos MeSH secundário: Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo
Animais
Antineoplásicos/farmacologia
Doxorrubicina/administração & dosagem
Doxorrubicina/farmacologia
Resistência a Múltiplos Medicamentos/efeitos dos fármacos
Feminino
Hematoporfirinas/química
Hematoporfirinas/farmacologia
Seres Humanos
Bicamadas Lipídicas/química
Lipossomos/química
Lipossomos/farmacologia
Células MCF-7
Camundongos Endogâmicos BALB C
Nanoestruturas/administração & dosagem
Nanoestruturas/química
Fármacos Fotossensibilizantes/farmacologia
Espécies Reativas de Oxigênio/metabolismo
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCB1 protein, human); 0 (ATP Binding Cassette Transporter, Sub-Family B); 0 (Antineoplastic Agents); 0 (Hematoporphyrins); 0 (Lipid Bilayers); 0 (Liposomes); 0 (Photosensitizing Agents); 0 (Reactive Oxygen Species); 0 (hematoporphyrin monomethyl ether); 80168379AG (Doxorubicin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S143776


  6 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778166
[Au] Autor:Fan R; Yuan Y; Zhang Q; Zhou XR; Jia L; Liu Z; Yu C; Luo SZ; Chen L
[Ad] Endereço:Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, People's Republic of China.
[Ti] Título:Isoleucine/leucine residues at "a" and "d" positions of a heptad repeat sequence are crucial for the cytolytic activity of a short anticancer lytic peptide.
[So] Source:Amino Acids;49(1):193-202, 2017 01.
[Is] ISSN:1438-2199
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:Many lytic peptides contain a heptad sequence with leucine or isoleucine residues at "a" and "d" positions. However, their roles in the peptide-induced cytolytic process remain unclear. We have recently reported an anticancer lytic peptide ZXR-2 (FKIGGFIKKLWRSLLA), which contains a shortened zipper-like sequence with Ile/Leu at "a" and "d" positions. To understand the roles of these Ile/Leu residues, a series of analogs were constructed by sequentially replacing the Ile or Leu residue with alanine (Ala). Significant reduction of the cytolytic activity was observed when the Ile (3rd and 7th) and Leu (10th and 14th) residues at the "a" and "d" positions were substituted, while the replacement of the separate Leu (15th) residue had less effect. Based on the quenching of the intrinsic fluorescence of the peptides and their induced surface pressure changes of lipid monolayer, it was conjectured that the peptide ZXR-2 might insert into cell membranes from the C-terminal and to a depth of the W position. Accordingly, I , I , and L residues which mainly exposed in aqueous solution were more responsible for the peptide self-association on cell membranes, while L , together with L , might help peptide insert and anchor to cell membranes. These results are significant to elucidate the crucial roles of such Ile/Leu residues at "a" and "d" positions in peptide-peptide and peptide-membrane interactions to exert the membrane disruption activity of lytic peptides. With further understanding about the structure-activity relationship of lytic peptides, it would be helpful for designing novel anticancer lytic peptides.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Isoleucina/química
Leucina/química
Peptídeos/farmacologia
[Mh] Termos MeSH secundário: 1,2-Dipalmitoilfosfatidilcolina/análogos & derivados
1,2-Dipalmitoilfosfatidilcolina/química
Alanina/química
Sequência de Aminoácidos
Substituição de Aminoácidos
Antineoplásicos/síntese química
Linhagem Celular Tumoral
Membrana Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Colesterol/química
Células HEK293
Células HeLa
Seres Humanos
L-Lactato Desidrogenase/secreção
Lipossomos/química
Peptídeos/síntese química
Fosfatidilserinas/química
Engenharia de Proteínas
Estrutura Secundária de Proteína
Eletricidade Estática
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Liposomes); 0 (Peptides); 0 (Phosphatidylserines); 04Y7590D77 (Isoleucine); 2644-64-6 (1,2-Dipalmitoylphosphatidylcholine); 3036-82-6 (dipalmitoylphosphatidylserine); 319X2NFW0A (colfosceril palmitate); 97C5T2UQ7J (Cholesterol); EC 1.1.1.27 (L-Lactate Dehydrogenase); GMW67QNF9C (Leucine); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s00726-016-2350-9


  7 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29442002
[Au] Autor:Vrbovská H; Babincová M
[Ti] Título:Comparative analysis of synthetic and nutraceutical antioxidants as possible neuroprotective agents.
[So] Source:Pharmazie;71(12):724-726, 2016 12 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Damage caused by oxidative stress in cases of neurodegenerative diseases such as Alzheimer's or Parkinson's has been proven to be irreversible. However, diet supplementation of antioxidants can be beneficial to the total antioxidant status of the human body. Given that oxidative stress is a principal cause of neurodegenerative disease, effective natural antioxidants could provide therapeutic options for these disorders. Therefore we investigated the antioxidant properties of two natural extracts and five synthetic compounds in lipid rich environment of liposomes with oxidation induced by Fenton's reagent. Antioxidant activity has been quantified using the Klein peroxidation index and oxygen uptake. Both natural extracts from Acai berry and Ginseng as well as all synthetic compounds - N-acetyl-L-cysteine, tocopherol, huperzines, caffeic acid and lipoic acid displayed good antioxidants properties, which confirm their suitability as neuroprotective agents.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Suplementos Nutricionais
Fármacos Neuroprotetores/farmacologia
[Mh] Termos MeSH secundário: Euterpe/química
Peróxido de Hidrogênio
Ferro
Peroxidação de Lipídeos/efeitos dos fármacos
Lipídeos/química
Lipossomos
Estresse Oxidativo/efeitos dos fármacos
Consumo de Oxigênio
Panax/química
Extratos Vegetais/química
Extratos Vegetais/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Fenton's reagent); 0 (Lipids); 0 (Liposomes); 0 (Neuroprotective Agents); 0 (Plant Extracts); BBX060AN9V (Hydrogen Peroxide); E1UOL152H7 (Iron)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6730


  8 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311523
[Au] Autor:Uyama M; Inoue K; Kinoshita K; Miyahara R; Yokoyama H; Nakano M
[Ad] Endereço:Shiseido Global Innovation Center.
[Ti] Título:Effect of Dialkyl Ammonium Cationic Surfactants on the Microfluidity of Membranes Containing Raft Domains.
[So] Source:J Oleo Sci;67(1):67-75, 2018.
[Is] ISSN:1347-3352
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:It has been reported that a lot of receptors localize in lipid raft domains and that the microfluidity of these domains regulates the activation of these receptors. In this study, we focused on the lipid raft and in order to evaluate the physicochemical effects of surfactants on microfluidity of lipid membranes, we used liposomes comprising of egg-yolk L-α-phosphatidylcholine, egg-yolk sphingomyelin, and cholesterol as a model of cell membranes containing raft domains. The microfluidity of the domains was characterized by fluorescence spectrometry using 1,6-diphenyl-1,3,5-hexatriene and 2-dimethylamino-6-lauroylnaphthalene. Among several surfactants, dialkylammonium-type cationic surfactants most efficiently increased the microfluidity. It is therefore concluded that (1) the electrostatic interaction between the cationic surfactant and eggPC/eggSM/cholesterol liposome could be important, (2) surfactants with alkyl chains more effectively inserted into membranes than those with acyl chains, and (3) cationic surfactants with lower T values have a greater ability to increase the fluidity.
[Mh] Termos MeSH primário: Compostos de Amônio
Membrana Celular
Fluidez de Membrana
Lipídeos de Membrana
Microdomínios da Membrana
Tensoativos
[Mh] Termos MeSH secundário: Cátions
Fenômenos Químicos
Colesterol
Gema de Ovo
Lipossomos
Fosfatidilcolinas
Espectrometria de Fluorescência
Esfingomielinas
Eletricidade Estática
Tensoativos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ammonium Compounds); 0 (Cations); 0 (Liposomes); 0 (Membrane Lipids); 0 (Phosphatidylcholines); 0 (Sphingomyelins); 0 (Surface-Active Agents); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.5650/jos.ess17124


  9 / 39553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173363
[Au] Autor:Feng C; Wang T; Zhang Y; Qu K; Tang S
[Ad] Endereço:Department of Pediatrics, Chinese PLA General Hospital, Beijing, China.
[Ti] Título:Novel Survivin-Targeted Small Interfering RNA Delivered by Nanoparticles.
[So] Source:Am J Med Sci;354(5):506-512, 2017 11.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The aim of the present study was to investigate the antitumor effect of our novel survivin-targeted small interfering RNA (siRNA) nanoliposomes on xenograft mouse models with human cervical carcinoma HeLa cells, and to evaluate pharmacokinetics. MATERIALS AND METHODS: siRNA nanoliposome was prepared and transfected into xenograft mouse models. Tumor growth in mice was determined and survivin expression was analyzed by using histologic and immunohischemical staining. Furthermore, low, moderate and high doses of survivin siRNA nanoliposomes were injected in 3 groups, and plasma concentrations were detected at various time points by reverse transcription quantitative polymerase chain reaction. Biodistribution of siRNA in tumor and other important organs were also determined. RESULTS: Survivin expression was significantly downregulated by survivin siRNA delivery mediated by nanoliposome, along with significant suppression of cell growth. Peak concentrations were obtained at 15 minutes after injection in each group, with 1,042,538.00, 6,837,099.54 and 14,631,333.15pg/mL, respectively, and the plasma concentration decreased significantly after 24 hours. The half-time life of survivin siRNA nanoliposomes in each group was 3.60, 2.64 and 2.80 hours, respectively. The area under curve values were 952,190.88, 6,800,687.79 and 13,803,680.96h/pg/mL, and the total drug clearance were 1,050.12, 441.13 and 434.67mL/h/kg. A significant accumulation of Cy5-labeled siRNA was found in the tumor, and a nonspecific accumulation was reduced significantly in lung. CONCLUSIONS: Our findings revealed that survivin suppression by siRNA may contribute to tumor inhibition through both proliferation inhibition and apoptosis promotion effect, and the pharmacokinetic characteristics serve as a fundamental role for further studies on its applicability for cancer therapy.
[Mh] Termos MeSH primário: Proteínas Inibidoras de Apoptose/farmacologia
Lipossomos/farmacologia
Nanopartículas/administração & dosagem
RNA Interferente Pequeno/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Proliferação Celular/efeitos dos fármacos
Regulação para Baixo/efeitos dos fármacos
Células HeLa
Seres Humanos
Proteínas Inibidoras de Apoptose/farmacocinética
Lipossomos/farmacocinética
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Nus
RNA Interferente Pequeno/administração & dosagem
RNA Interferente Pequeno/farmacocinética
Distribuição Tecidual
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (BIRC5 protein, human); 0 (Inhibitor of Apoptosis Proteins); 0 (Liposomes); 0 (RNA, Small Interfering)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  10 / 39553 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28744121
[Au] Autor:Çelik B; Sagiroglu AA; Özdemir S
[Ad] Endereço:Department of Pharmaceutical Technology, Faculty of Pharmacy, Bezmialem Vakif University.
[Ti] Título:Design, optimization and characterization of coenzyme Q10- and D-panthenyl triacetate-loaded liposomes.
[So] Source:Int J Nanomedicine;12:4869-4878, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Coenzyme Q10 (CoQ10) is a lipid-soluble molecule found naturally in many eukaryotic cells and is essential for electron transport chain and energy generation in mitochondria. D-Panthenyl triacetate (PTA) is an oil-soluble derivative of D-panthenol, which is essential for coenzyme A synthesis in the epithelium. Liposomal formulations that encapsulate both ingredients were prepared and optimized by applying response surface methodology for increased stability and skin penetration. The optimum formulation comprised 4.17 mg CoQ10, 4.22 mg PTA and 13.95 mg cholesterol per 100 mg of soy phosphatidylcholine. The encapsulation efficiency of the optimized formulation for CoQ10 and PTA was found to be 90.89%±3.61% and 87.84%±4.61%, respectively. Narrow size distribution was achieved with an average size of 161.6±3.6 nm, while a spherical and uniform shape was confirmed via scanning electron microscopy and transmission electron microscopy images. Cumulative release of 90.93% for PTA and 24.41% for CoQ10 was achieved after 24 hours of in vitro release study in sink conditions. Physical stability tests indicated that the optimized liposomes were suitable for storage at 4°C for at least 60 days. The results suggest that the optimized liposomal formulation would be a promising delivery system for both ingredients in various topical applications.
[Mh] Termos MeSH primário: Lipossomos/química
Ácido Pantotênico/análise
Ácido Pantotênico/química
Ubiquinona/análogos & derivados
[Mh] Termos MeSH secundário: Colesterol/química
Liberação Controlada de Fármacos
Estabilidade de Medicamentos
Microscopia Eletrônica de Varredura
Microscopia Eletrônica de Transmissão
Ácido Pantotênico/análogos & derivados
Tamanho da Partícula
Ubiquinona/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Liposomes); 1339-63-5 (Ubiquinone); 19F5HK2737 (Pantothenic Acid); 1O6C93RI7Z (dexpanthenol); 97C5T2UQ7J (Cholesterol); EJ27X76M46 (coenzyme Q10)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S140835



página 1 de 3956 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde